The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care?
In a prospective study of 20 patients with NMS, those who received dantrolene (2 patients) or bromocriptine (2 patients) or both (4 patients) tended to have a more prolonged course of illness and a greater incidence of sequelae than those treated with supportive care alone. These results do not indicate a useful role for dantrolene or bromocriptine in the treatment of NMS.
Rosebush
P I
PI
Department of Psychiatry, McMaster University Medical Centre, Hamilton, Ontario, Canada.
Stewart
T
T
Mazurek
M F
MF
D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003422:Critical Care; D003620:Dantrolene / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000188:drug therapy*; D009460:Neurologic Examination; D011446:Prospective Studies
D001971:Bromocriptine; D003620:Dantrolene